


Breakthrough ANGPTL3-Lowering Therapy Market Set to Revolutionize Cardiovascular Treatment — Explosive Growth 2025-2033

The Global ANGPTL3-Lowering Therapy Market is expected to reach at a CAGR of 30.9% during the forecast period 2025-2033.

AUSTIN, TX, UNITED STATES, August 12, 2025 /EINPresswire.com/ -- According to DataM Intelligence, The [ANGPTL3-Lowering Therapy Market](#) reached US\$ 99.75 Million in 2024 and is expected to reach US\$ 1,096.42 Million by 2033, growing at a CAGR of 30.9% between 2025 and 2033. Rising prevalence of cardiovascular diseases, growing awareness of lipid management, advancements in ANGPTL3-targeted therapies, increasing healthcare investments, and unmet needs in treating hyperlipidemia drive market growth.



To Download Sample Report Here: <https://www.datamintelligence.com/download-sample/angptl3-lowering-therapy-market>

“

ChatGPT said:

The ANGPTL3-Lowering Therapy Market is rapidly growing, driven by rising cardiovascular diseases and innovative treatments targeting lipid regulation for improved patient outcomes.”

DataM Intelligence

Market Drivers and Opportunities:

Key factors driving the growth of the ANGPTL3-lowering therapy market include:

Rising Prevalence of Hyperlipidemia and Cardiovascular Diseases: Elevated LDL-C and triglyceride levels are major contributors to atherosclerotic cardiovascular diseases, leading to increased demand for effective lipid-lowering therapies.

Unmet Medical Needs: Traditional lipid-lowering agents often fall short in patients with severe or

genetic lipid disorders, creating a significant opportunity for ANGPTL3-targeted therapies.

Advancements in Gene Editing: Companies like Verve Therapeutics and CRISPR Therapeutics are developing gene-editing therapies that offer potential long-term solutions for lipid management.

Market Segmentation:

By Treatment Type:

Monoclonal Antibodies

Antisense Oligonucleotides (ASOs)

RNA Interference (RNAi) Therapies (siRNA)

CRISPR-Based Gene Editing

Others.

By Application:

Familial Hypercholesterolemia (FH)

Refractory Hyperlipidemia

Mixed Dyslipidemia

Cardiovascular Diseases

Others.

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East

Africa.

Buy Now & Unlock 360° Market Intelligence: <https://www.datamintelligence.com/buy-now-page?report=angptl3-lowering-therapy-market>

Market Geographical Share:

North America is expected to hold a substantial share of the global ANGPTL3-lowering therapy market, driven by high rates of hyperlipidemia and cardiovascular diseases, advanced healthcare infrastructure, and significant investment in research and development.

Key Market Players:

Prominent companies operating in the ANGPTL3-lowering therapy market include:

Regeneron Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Inc.
Amgen Inc.
Ionis Pharmaceuticals, Inc. (Akcea Therapeutics)
Silence Therapeutics
Eli Lilly and Company
Novartis AG
Verve Therapeutics, Inc.
CRISPR Therapeutics.

Recent Developments:

United States:

March 2025: Verve Therapeutics announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for VERVE-102, allowing the company to begin clinical trials in the United States.

April 2025: CRISPR Therapeutics reported that its gene-editing therapy targeting ANGPTL3 resulted in a two-thirds reduction in LDL-C levels among the first 10 patients treated, with no serious side effects observed in the initial months.

Japan:

November 2024: A Japanese research team published findings demonstrating that ANGPTL3 inhibition effectively reduced LDL-C and triglyceride levels in animal models, paving the way for clinical trials in Japan.

January 2025: Japanese pharmaceutical company Daiichi Sankyo announced the initiation of a Phase 1 clinical trial for its ANGPTL3-targeted monoclonal antibody, aiming to evaluate its safety and efficacy in healthy volunteers.

Unlock 360° Market Intelligence with DataM Subscription Services:

<https://www.datamintelligence.com/reports-subscription>

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights-all in one place.

Competitive Landscape

Sustainability Impact Analysis

KOL / Stakeholder Insights

Unmet Needs & Positioning, Pricing & Market Access Snapshots

Market Volatility & Emerging Risks Analysis

Quarterly Industry Report Updated

Live Market & Pricing Trends

Consumer Behavior & Demand Analysis

Have a look at our Subscription Dashbord: <https://www.youtube.com/watch?v=x5oEiqEqTWg>

Conclusion:

The ANGPTL3-lowering Therapy Market is set for robust growth, driven by the increasing burden of cardiovascular diseases and advancements in therapeutic options. With ongoing research and development efforts, particularly in gene-editing technologies, the market is poised to offer innovative solutions for patients with challenging lipid disorders. Stakeholders in the healthcare industry should closely monitor these developments to capitalize on emerging opportunities in this dynamic market.

Related Reports:

[Lipid Disorder Treatment Market](#)

[Lipid-regulating Drugs Market](#)

Sai Kiran

DataM Intelligence 4Market Research

+1 877-441-4866

Sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/839064638>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.